What factors influence long-term antidepressant use in primary care? Findings from the Australian diamond cohort study

2015 ◽  
Vol 176 ◽  
pp. 125-132 ◽  
Author(s):  
Gilles Ambresin ◽  
Victoria Palmer ◽  
Konstancja Densley ◽  
Christopher Dowrick ◽  
Gail Gilchrist ◽  
...  
2016 ◽  
Vol 66 (651) ◽  
pp. e708-e719 ◽  
Author(s):  
Renske C Bosman ◽  
Klaas M Huijbregts ◽  
Peter FM Verhaak ◽  
Henricus G Ruhé ◽  
Harm WJ van Marwijk ◽  
...  

PLoS Medicine ◽  
2021 ◽  
Vol 18 (6) ◽  
pp. e1003631
Author(s):  
Tara Gomes ◽  
Tonya J. Campbell ◽  
Diana Martins ◽  
J. Michael Paterson ◽  
Laura Robertson ◽  
...  

Background Stigma and high-care needs can present barriers to the provision of high-quality primary care for people with opioid use disorder (OUD) and those prescribed opioids for chronic pain. We explored the likelihood of securing a new primary care provider (PCP) among people with varying histories of opioid use who had recently lost access to their PCP. Methods and findings We conducted a retrospective cohort study using linked administrative data among residents of Ontario, Canada whose enrolment with a physician practicing in a primary care enrolment model (PEM) was terminated between January 2016 and December 2017. We assigned individuals to 3 groups based upon their opioid use on the date enrolment ended: long-term opioid pain therapy (OPT), opioid agonist therapy (OAT), or no opioid. We fit multivariable models assessing the primary outcome of primary care reattachment within 1 year, adjusting for demographic characteristics, clinical comorbidities, and health services utilization. Secondary outcomes included rates of emergency department (ED) visits and opioid toxicity events. Among 154,970 Ontarians who lost their PCP, 1,727 (1.1%) were OAT recipients, 3,644 (2.4%) were receiving long-term OPT, and 149,599 (96.5%) had no recent prescription opioid exposure. In general, OAT recipients were younger (median age 36) than those receiving long-term OPT (59 years) and those with no recent prescription opioid exposure (44 years). In all exposure groups, the majority of individuals had their enrolment terminated by their physician (range 78.1% to 88.8%). In the primary analysis, as compared to those not receiving opioids, OAT recipients were significantly less likely to find a PCP within 1 year (adjusted hazard ratio [aHR] 0.55, 95% confidence interval [CI] 0.50 to 0.61, p < 0.0001). We observed no significant difference between long-term OPT and opioid unexposed individuals (aHR 0.96; 95% CI 0.92 to 1.01, p = 0.12). In our secondary analysis comparing the period of PCP loss to the year prior, we found that rates of ED visits were elevated among people not receiving opioids (adjusted rate ratio (aRR) 1.20, 95% CI 1.18 to 1.22, p < 0.0001) and people receiving long-term OPT (aRR 1.37, 95% CI 1.28 to 1.48, p < 0.0001). We found no such increase among OAT recipients, and no significant increase in opioid toxicity events in the period following provider loss for any exposure group. The main limitation of our findings relates to their generalizability outside of PEMs and in jurisdictions with different financial incentives incorporated into primary care provision. Conclusions In this study, we observed gaps in access to primary care among people who receive prescription opioids, particularly among OAT recipients. Ongoing efforts are needed to address the stigma, discrimination, and financial disincentives that may introduce barriers to the healthcare system, and to facilitate access to high-quality, consistent primary care services for chronic pain patients and those with OUD.


BMJ Open ◽  
2019 ◽  
Vol 9 (12) ◽  
pp. e033545 ◽  
Author(s):  
Kristjan Linnet ◽  
Johann Agust Sigurdsson ◽  
Margret Olafia Tomasdottir ◽  
Emil Larus Sigurdsson ◽  
Larus Steinthor Gudmundsson

ObjectivesTo assess the risk of mortality in primary care patients, multimorbid (≥2 chronic conditions) or not, prescribed hypnotics/anxiolytics.DesignA longitudinal cohort studySettingPrimary healthcare in the Reykjavik area.Participants114 084 individuals (aged 10–79 years, average 38.5, SD 18.4) contacting general practitioners during 2009–2012 (mortality follow-up to 31 December 2016). Of those, the reference group comprised 58 560 persons who were neither multimorbid nor had redeemed prescriptions for hypnotics/anxiolytics. Participants (16 108) redeeming prescriptions for hypnotics/anxiolytics on a regular basis for 3 consecutive years were considered as consistent, long-term users. They were subdivided into low-dose (1–300 defined daily doses (DDD)/3 years), medium-dose (301–1095 DDDs/3 years) and high-dose users (>1095 DDDs/3 years). All six groups taking these drugs were compared with the reference group.Main outcome measuresAll-cause mortality.ResultsHRs were calculated with the no multimorbidity—no drug group as a reference, using Cox proportional hazards regression model adjusting for age, sex and the number of chronic conditions (n=111 767), patients with cancer excluded. During follow-up, 516 358 person-years in total, 1926 persons died. Mean follow-up was 1685 days (4.6 years), range 1–1826 days (5.0 years). For all multimorbid patients who took no drugs the HR was 1.14 (95% CI 1.00 to 1.30) compared with those without multimorbidity. HRs in the non-multimorbid participants varied from 1.49 to 3.35 (95% CI ranging from 1.03 to 4.11) with increasing doses of hypnotics/anxiolytics, and correspondingly from 1.55 to 3.52 (1.18 to 4.29) in multimorbid patients.ConclusionsMortality increased in a dose-dependent manner among both multimorbid and non-multimorbid patients taking hypnotics/anxiolytics. This increase was clearly associated with prescribing of these drugs. Their use should be limited to the recommended period of 2–4 up to 6 weeks; long-term use may incur increased risk and should be re-examined.


2015 ◽  
Vol 15 (1) ◽  
Author(s):  
Trevor Hill ◽  
Carol Coupland ◽  
Richard Morriss ◽  
Antony Arthur ◽  
Michael Moore ◽  
...  

1992 ◽  
Vol 26 (3) ◽  
pp. 373-377 ◽  
Author(s):  
Ronald B. Stewart ◽  
Dag G.L. Isacson ◽  
Kerstin A.L. Bingefors ◽  
Karolina I.M. Antonov

OBJECTIVE: Analysis of long-term use of neuroleptics among the elderly in a Swedish community. DESIGN: Cohort study, three-year follow-up period. SETTING: Primary care. PATIENTS: All people aged 65 years or older who used neuroleptics in 1984. RESULTS: Neuroleptic use was fairly common among elderly and continued long-term use was relatively frequent. One third of long-term users obtained doses exceeding a recommended dosage range. Prescribed doses were seldom changed during the study period. CONCLUSIONS: The high proportion of long-term users and the stability of the prescribed doses indicate that there is a need for more information to be made available to prescribers regarding the risks of long-term use of neuroleptics in primary care.


2020 ◽  
Author(s):  
Anna-Sophie Rommel ◽  
Natalie C. Momen ◽  
Nina Maren Molenaar ◽  
Xiaoqin Liu ◽  
Trine Munk-Olsen ◽  
...  

BMJ ◽  
2015 ◽  
Vol 350 (feb18 32) ◽  
pp. h517-h517 ◽  
Author(s):  
C. Coupland ◽  
T. Hill ◽  
R. Morriss ◽  
A. Arthur ◽  
M. Moore ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document